Development of a Nomogram Combining Preoperative Serum CA19-9 and VEGF to Predict Lymph Node Metastasis in Colorectal Cancer

Colorectal cancer is a disease where growths form in the large intestine or rectum, and one of the most critical factors in determining a patient's future is whether those growths have spread to nearby lymph nodes. These small, bean-shaped structures act as filters for the immune system, but when cancer cells travel there, the disease becomes more difficult to treat and the outlook for the patient grows dimmer. Currently, doctors rely heavily on imaging scans like CT or MRI to check for this spread before surgery, but these tools have a blind spot. They are excellent at spotting large lumps, yet they often miss tiny clusters of cancer cells that have already begun to travel, leading to situations where a surgeon might remove too little tissue or, conversely, remove too much. To bridge this gap, medical researchers have long looked for chemical signals in the blood that could act as early warning systems, hoping to find a way to see the invisible spread of the disease before a single incision is made.

A team of researchers at the First Affiliated Hospital of Guangxi Medical University in China set out to solve this specific problem by creating a new tool to predict lymph node spread more accurately. They focused on two specific substances found in the blood: CA19-9, a protein often elevated in digestive cancers, and VEGF, a factor that helps tumors build new blood and lymph vessels. While doctors have known for some time that high levels of these substances can be a sign of trouble, this study asked a different question: could combining these blood markers with standard information about the tumor itself create a much sharper picture of the risk? The researchers gathered data from over one thousand patients who had undergone successful surgery for colorectal cancer between 2019 and 2022. They carefully reviewed the medical records, blood test results, and pathology reports from these patients to understand exactly what happened after the surgery.

The team split these patients into two groups to ensure their findings were robust. They used the larger group to build a new prediction model and the smaller group to test if that model worked on people it had never seen before. Through a rigorous statistical process, they identified five key factors that independently predicted whether cancer had reached the lymph nodes. Two of these were the blood markers they had set out to study: patients with CA19-9 levels above 37.0 units per milliliter and those with VEGF levels above 186.8 picograms per milliliter were significantly more likely to have spread. The other three factors were details found in the tissue after surgery: how deeply the tumor had grown into the intestinal wall, how abnormal the cancer cells looked under a microscope, and whether the cancer cells had invaded nearby blood or lymph vessels.

Using these five factors, the researchers constructed a visual tool called a nomogram. This is essentially a specialized chart that allows a doctor to take a specific patient's data and calculate a personalized risk score. To use it, a clinician locates the patient's values for each of the five factors on the chart, adds up the corresponding points, and draws a line down to find the estimated probability of lymph node metastasis. The study found that this combined approach was far superior to looking at the blood markers alone. While the blood markers by themselves offered only a moderate ability to distinguish between patients with and without spread, the new model correctly ranked patients with a high degree of accuracy, achieving a score that placed it well above the performance of standard imaging or single markers.

The results showed that the model was not only accurate but also reliable. When tested on the second group of patients, the tool performed almost as well as it did on the group used to build it, suggesting it is not just a fluke of the specific data set. The researchers also analyzed whether using this tool would actually help doctors make better decisions. They found that across a wide range of risk thresholds, the model offered a clear clinical benefit, helping to distinguish between patients who might need more aggressive treatment and those who could avoid it. However, the authors are careful to note that this tool currently relies on some information that is only available after the tumor has been removed, such as the depth of invasion and the presence of vessel invasion. This means that while the blood tests can be done before surgery, the full power of the chart is realized once the pathology report is in hand.

The study concludes that integrating simple blood tests with standard pathological findings creates a powerful method for assessing risk in colorectal cancer. By combining the biological signals of CA19-9 and VEGF with the physical characteristics of the tumor, doctors gain a more complete understanding of the disease's behavior. The researchers emphasize that while their tool shows great promise, it must now be tested in other hospitals and with different patient populations to confirm that it works universally. Until then, this new chart stands as a significant step forward, offering a way to see the invisible spread of cancer with greater clarity and helping to tailor treatment to the individual needs of each patient.